NEW YORK, Jan. 5 (GenomeWeb News) - Galapagos has licensed asthma and allergy drug targets to GlaxoSmithKline and will identify further targets for the drug maker, the Mechelen, Belgium-based company said today.
Registering provides access to this and other free content.
Already have an account?Login Now.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.